Research in progress · 2026 edition
Get the preview and join the full-report waitlist
The State of Aesthetic Devices 2026 — a catalog of US-marketed aesthetic and wellness devices, in progress. The preview numbers below are real, computed from the live index and refreshed on a short cache cycle. The written report is still being finalized — join the waitlist and we'll send it the day it publishes.
Preview: the census so far
485 US-marketed devices · 382 with a 510(k) clearance number on the record · 198 manufacturers · 59 chains · 122 documented chain–device pairings · catalog checked 23 Sep 2026
485
Devices in the US census
198
Manufacturers tracked
122
Documented chain→device pairings across 36 chain fleets
70
Curated head-to-head comparisons
FDA status breakdown
Computed live from the catalog as of Sep 23, 2026.
Devices per category
Computed live from the catalog as of Sep 23, 2026.
Consumable lock-in
Computed live from the catalog as of Sep 23, 2026.
FDA status of all 485 devices
- 382 FDA cleared
- 55 Registered or general wellness
- 46 Not FDA cleared
- 2 No US 510(k) located
As of September 23, 2026
Explore the research
Download aggregate statistics or ask about research access for your project.
Free summary
FDA status breakdown
Catalog-wide counts by FDA status. Updated from the live index, with no individual device records.
Download summary CSVCC BY 4.0. Reuse with attribution and a link to The Aesthetic Index.
Research access
Need structured research?
Tell us which devices or markets you study and how you plan to use the data. We review requests for scope, availability and licensing.
Ask about research accessBulk catalog and chain exports are not public downloads. Sending a request does not unlock data.
What the full report will cover
- Category-by-category regulatory posture, including how often marketed claims run ahead of the cleared indication.
- New versus used pricing dispersion, and where the secondary market actually clears.
- Consumable lock-in: recurring cost per treatment as a share of realistic treatment revenue.
- The platforms the largest US medspa chains standardize on, and what that signals about service and resale.
- Full methodology, sourcing notes and data limitations.
Curious how the underlying data is checked? Read our methodology.
Join the waitlist
The written report hasn't published yet. Leave your email and you'll get it free the day it ships, plus future editions.
Evidence-led research under a published editorial policy. Editorial content and FDA data are never for sale.